Vadadustat
|
|
|
- CAS-Nr.
- 1000025-07-9
- Englisch Name:
- Vadadustat
- Synonyma:
- 2-(5-(3-chlorophenyl)-3-hydroxypicolinamido)acetic acid;CS-2486;AKB-6548;Valdesta;PG1016548;PG-1016548;Vadadustat;PG 1016548;Vardorestat;Vadadustat 13C6
- CBNumber:
- CB73147387
- Summenformel:
- C14H11ClN2O4
- Molgewicht:
- 306.7
- MOL-Datei:
- 1000025-07-9.mol
|
Vadadustat Eigenschaften
- Schmelzpunkt:
- 172-174°C
- Siedepunkt:
- 674.6±55.0 °C(Predicted)
- Dichte
- 1.461±0.06 g/cm3(Predicted)
- storage temp.
- Hygroscopic, -20°C Freezer, Under inert atmosphere
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 4.09±0.40(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Pale Beige to Light Beige
- Stabilit?t:
- Hygroscopic
- InChI
- InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
- InChIKey
- JGRXMPYUTJLTKT-UHFFFAOYSA-N
- SMILES
- C(O)(=O)CNC(C1=NC=C(C2=CC=CC(Cl)=C2)C=C1O)=O
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Vadadustat Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Vadadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3 (IC
50s = 1.1 and 0.39 micromolar, respectively). It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.
Verwenden
Vadadustat is a novel HIF (Hypoxia-inducible factor) stabilizer. It provides an effective anemia treatment in nondialysis-dependent chronic kidney disease.
Mechanism of action
Vadadustat inhibits PDH and reduces the degradation of HIF-α, thereby increasing the production of endogenous erythropoietin (EPO) and improving anemia symptoms.
Sicherheit(Safety)
Phase 3 clinical trials in Japan have confirmed the efficacy and safety of vadadustat for the treatment of renal anemia in patients with both non-dialysis-dependent (NDD)-chronic kidney disease (CKD) and dialysis-dependent CKD. The incidence of adverse events (AEs) and serious AEs in the vadadustat treatment group was comparable to that observed in the erythropoiesis-stimulating agents (ESA) treatment group
[2].
Synthese
Boronic acid 69 and pyridine nitrile 70 were coupled via Suzuki coupling to give biphenyl 71. Crystallization of 71 was required to remove small amounts of undesired regioisomer coupling products. One-pot reaction: aromatic substitution with methoxy anion. Hydrolysis of the nitrile was performed simultaneously. These two independent operations were performed in one pot to give compound 72 in 92% overall yield for the two steps. Carboxylic acid 72 and amine 73 were amidated using CDI (carbodiimide) as coupling agent to give compound 74. Aluminum-mediated demethylation of 74 removed the ester and ether functionalities to give vadadustat (XI) in 84% yield.
Vadadustat Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Vadadustat Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 110)Lieferanten
- Vadadustat
- AKB-6548; AKB 6548; AKB6548; PG-1016548; PG 1016548; PG1016548; B-506; B506; VADADUSTAT
- PG-1016548;AKB-6548
- Vadadustat(AKB-6548/PG-1016548)
- Vadadustat (AKB-6548)
- AKB-6548
- PG 1016548
- PG1016548
- PG-1016548
- PG-1016548; PG1016548; PG 1016548; AKB-6548
- CS-2486
- Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-
- Vadadustat USP/EP/BP
- Vadadustat (PG-1016548
- Vadadustat 13C6
- Valdesta
- disease,HIFs,AKB 6548,Erythropoiesis-stimulating,kidney,Inhibitor,AKB6548,inhibit,Vadadustat,HIF-PH,PG 1016548,anemia,Hypoxia-inducible factors,PG1016548,nondialysis-dependent,HIF/HIF Prolyl-Hydroxylase,chronic
- Vardorestat
- 2-[[[5-(3-Chlorophenyl)-3-hydroxypyridin-2-yl]carbonyl]amino]acetic acid
- (5-(3-chlorophenyl)-3-hydroxypicolinoyl)glycine
- 2-(5-(3-chlorophenyl)-3-hydroxypicolinamido)acetic acid
- 1000025-07-9
- API
